Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders

The following table sets forth the computation of basic and diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2024 and 2023, respectively (in thousands, except share and per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Net loss attributable to Adaptive Biotechnologies Corporation	$	(46,222	)	$	(47,810	)	$	(93,729	)	$	(105,509	)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted		147,414,095			144,397,693			146,600,811			143,956,867
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted	$	(0.31	)	$	(0.33	)	$	(0.64	)	$	(0.73	)

Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to our common shareholders for the three and six months ended June 30, 2024 and 2023, respectively, as they had an anti-dilutive effect:

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Stock options outstanding		13,055,050		14,556,602		13,070,461		14,180,632
Nonvested restricted stock units outstanding		11,174,598		11,007,405		10,757,897		8,956,361
Maximum nonvested market-based restricted stock units outstanding eligible to be earned		3,771,579		1,912,674		3,159,668		1,411,126
Total		28,001,227		27,476,681		26,988,026		24,548,119